瑞德西韦在 2019 冠状病毒病大流行中的应用：小型综述。
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
机构信息
Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
J Microbiol Immunol Infect. 2021 Feb;54(1):27-36. doi: 10.1016/j.jmii.2020.09.002. Epub 2020 Oct 5.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是导致 2019 年冠状病毒病（COVID-19）的病原体病毒，它似乎有多种临床表现，并可能导致严重的呼吸衰竭。2019 年 12 月，中国首次报告了与全球 SARS-CoV-2 相关的病毒性肺炎大流行。基于已知的药理学机制，许多治疗药物已被重新用于针对 SARS-CoV-2。在这些药物中，根据几项临床试验和同情用药的报告，瑞德西韦似乎是目前最有希望的药物。在这篇迷你综述中，我们总结了瑞德西韦治疗 2019 年冠状病毒病（COVID-19）的疗效和挑战的现有证据。
相似文献
1
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.瑞德西韦在 2019 冠状病毒病大流行中的应用：小型综述。
J Microbiol Immunol Infect. 2021 Feb;54(1):27-36. doi: 10.1016/j.jmii.2020.09.002. Epub 2020 Oct 5.
2
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.评估静脉用瑞德西韦治疗成人重症 COVID-19 的疗效和安全性：一项 3 期随机、双盲、安慰剂对照、多中心试验的研究方案。
Trials. 2020 May 24;21(1):422. doi: 10.1186/s13063-020-04352-9.
3
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.瑞德西韦：针对 COVID-19 的药理学、临床前数据和新兴临床经验综述。
Pharmacotherapy. 2020 Jul;40(7):659-671. doi: 10.1002/phar.2429. Epub 2020 Jun 28.
4
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.瑞德西韦（GS-5734）在 COVID-19 治疗中的第四次机会。
Curr Drug Targets. 2021;22(12):1346-1356. doi: 10.2174/1389450121999201202110303.
5
Rapid review for the anti-coronavirus effect of remdesivir.瑞德西韦抗冠状病毒作用的快速综述。
Drug Discov Ther. 2020;14(2):73-76. doi: 10.5582/ddt.2020.01015.
6
A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.基于雾化瑞德西韦治疗 SARS-CoV-2 肺部炎症的新型药理学方法：一种合理的治疗应用。
Med Hypotheses. 2020 Nov;144:109876. doi: 10.1016/j.mehy.2020.109876. Epub 2020 May 24.
7
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.瑞德西韦：一种有前景的 COVID-19 大流行抗病毒候选药物：小型综述。
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
8
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
9
Antiviral treatment for COVID-19: the evidence supporting remdesivir.针对 COVID-19 的抗病毒治疗：瑞德西韦的证据支持。
Clin Med (Lond). 2020 Nov;20(6):e215-e217. doi: 10.7861/clinmed.2020-0524. Epub 2020 Aug 30.
10
A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.瑞德西韦：一种广谱抗病毒药物分子，可能用于治疗 COVID-19。
Mini Rev Med Chem. 2021;21(17):2530-2543. doi: 10.2174/1389557521666210217093004.
引用本文的文献
1
Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.新冠病毒已批准和重新利用的抗病毒药物的比较药物警戒分析：来自欧洲药品管理局药物警戒数据库（EudraVigilance）数据的见解
Biomedicines. 2025 Jun 5;13(6):1387. doi: 10.3390/biomedicines13061387.
2
Clinical outcomes and considerations in outpatient with COVID-19 receiving remdesivir therapy.接受瑞德西韦治疗的门诊COVID-19患者的临床结局及考量因素
Health Sci Rep. 2024 Jul 22;7(7):e2252. doi: 10.1002/hsr2.2252. eCollection 2024 Jul.
3
Disparate viral pandemics from COVID19 to monkeypox and beyond: a simple, effective and universal therapeutic approach hiding in plain sight.从 COVID19 到猴痘再到其他病毒大流行：一种简单、有效且通用的治疗方法，显而易见却被忽视。
Front Immunol. 2023 Dec 1;14:1208828. doi: 10.3389/fimmu.2023.1208828. eCollection 2023.
4
Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza.比较因 COVID-19 和流感住院后的急性后期后遗症。
BMC Med. 2023 Dec 5;21(1):480. doi: 10.1186/s12916-023-03200-2.
5
Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后复发。
J Med Virol. 2023 Feb;95(2):e28430. doi: 10.1002/jmv.28430.
6
Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.肺部药物递送：抗击 COVID-19 的有效且便捷的给药途径。
Drug Deliv Transl Res. 2023 Mar;13(3):705-715. doi: 10.1007/s13346-022-01251-1. Epub 2022 Oct 19.
7
Cuttlefish bone powder as an efficient solid-phase extraction sorbent of anti-SARS-CoV-2 drugs in environmental water.乌贼骨粉作为环境水中抗SARS-CoV-2药物的高效固相萃取吸附剂。
Chem Zvesti. 2022;76(11):6941-6951. doi: 10.1007/s11696-022-02388-6. Epub 2022 Jul 30.
8
Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission.两亲性抗 SARS-CoV-2 药物瑞德西韦整合进入脂质双层和神经末梢膜，影响兴奋性和抑制性神经递质传递。
Biochim Biophys Acta Biomembr. 2022 Aug 1;1864(8):183945. doi: 10.1016/j.bbamem.2022.183945. Epub 2022 Apr 22.
9
Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.大多数已发表的关于瑞德西韦治疗 COVID-19 的系统评价都是多余的，且缺乏时效性。
J Clin Epidemiol. 2022 Jun;146:22-31. doi: 10.1016/j.jclinepi.2022.02.006. Epub 2022 Feb 19.
10
Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.褪黑素：强调其在治疗 SARS-CoV-2 感染方面的潜在用途。
Cell Mol Life Sci. 2022 Feb 20;79(3):143. doi: 10.1007/s00018-021-04102-3.
本文引用的文献
1
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响：一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.新冠康复期血浆输注与危重症COVID-19患者临床改善相关：一项初步研究。
Rev Invest Clin. 2020;72(3):159-164. doi: 10.24875/RIC.20000237.
4
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
5
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.在新冠疫情期间，类似新冠病毒感染的检查点抑制剂肺炎。
Lung Cancer. 2020 Aug;146:376-377. doi: 10.1016/j.lungcan.2020.06.013. Epub 2020 Jun 17.
6
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?瑞德西韦的现有证据及正在进行的临床试验：它会是治疗新冠病毒病的一个有前景的疗法吗？
Front Pharmacol. 2020 May 26;11:791. doi: 10.3389/fphar.2020.00791. eCollection 2020.
7
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.瑞德西韦：一种有前景的 COVID-19 大流行抗病毒候选药物：小型综述。
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
8
Uncertainty about the Efficacy of Remdesivir on COVID-19.瑞德西韦对COVID-19疗效的不确定性。
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
9
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.瑞德西韦在感染 SARS-CoV-2 的恒河猴中的临床获益。
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
10
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.瑞德西韦用于急性或慢性肾脏病合并新型冠状病毒肺炎患者的研究
J Am Soc Nephrol. 2020 Jul;31(7):1384-1386. doi: 10.1681/ASN.2020050589. Epub 2020 Jun 8.
Zotero 插件